WO2005077332A3 - Stable sustained-release oral dosage forms of gabapentin and process for preparation thereof - Google Patents

Stable sustained-release oral dosage forms of gabapentin and process for preparation thereof Download PDF

Info

Publication number
WO2005077332A3
WO2005077332A3 PCT/IB2005/000093 IB2005000093W WO2005077332A3 WO 2005077332 A3 WO2005077332 A3 WO 2005077332A3 IB 2005000093 W IB2005000093 W IB 2005000093W WO 2005077332 A3 WO2005077332 A3 WO 2005077332A3
Authority
WO
WIPO (PCT)
Prior art keywords
gabapentin
preparation
dosage forms
oral dosage
release oral
Prior art date
Application number
PCT/IB2005/000093
Other languages
French (fr)
Other versions
WO2005077332A2 (en
Inventor
Manish Chawla
Rajeev Singh Raghuvanshi
Ashok Rampal
Original Assignee
Ranbaxy Lab Ltd
Manish Chawla
Rajeev Singh Raghuvanshi
Ashok Rampal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Manish Chawla, Rajeev Singh Raghuvanshi, Ashok Rampal filed Critical Ranbaxy Lab Ltd
Publication of WO2005077332A2 publication Critical patent/WO2005077332A2/en
Publication of WO2005077332A3 publication Critical patent/WO2005077332A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The present invention relates to stable sustained-release oral dosage forms of gabapentin, processes for preparation thereof, and uses thereof in treating epilepsy or post herpetic neuralgia.
PCT/IB2005/000093 2004-01-19 2005-01-17 Stable sustained-release oral dosage forms of gabapentin and process for preparation thereof WO2005077332A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN83DE2004 2004-01-19
IN83/DEL/2004 2004-01-19

Publications (2)

Publication Number Publication Date
WO2005077332A2 WO2005077332A2 (en) 2005-08-25
WO2005077332A3 true WO2005077332A3 (en) 2006-07-27

Family

ID=34856866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000093 WO2005077332A2 (en) 2004-01-19 2005-01-17 Stable sustained-release oral dosage forms of gabapentin and process for preparation thereof

Country Status (2)

Country Link
CN (1) CN1921839A (en)
WO (1) WO2005077332A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077492A1 (en) * 2005-01-24 2006-07-27 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
CN104352460A (en) * 2014-10-21 2015-02-18 齐宏 Gabapentin tablet and preparation method thereof
CN106333927A (en) * 2015-07-08 2017-01-18 昆山龙灯瑞迪制药有限公司 Modified-release nicergoline composition
CN110917164B (en) * 2019-12-17 2022-03-29 南京康川济医药科技有限公司 Milopalin besylate sustained-release tablets and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059572A1 (en) * 1998-05-15 1999-11-25 Warner-Lambert Company Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
WO2003035040A1 (en) * 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
WO2003103634A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin
WO2005020978A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited Sustained release oral tablets of gabapentin and process for their preparation
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059572A1 (en) * 1998-05-15 1999-11-25 Warner-Lambert Company Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
WO2003035040A1 (en) * 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
WO2003103634A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
WO2005020978A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited Sustained release oral tablets of gabapentin and process for their preparation

Also Published As

Publication number Publication date
WO2005077332A2 (en) 2005-08-25
CN1921839A (en) 2007-02-28

Similar Documents

Publication Publication Date Title
WO2005077332A3 (en) Stable sustained-release oral dosage forms of gabapentin and process for preparation thereof
JO2858B1 (en) Pharmaceutical Dosage Forms
WO2003063794A3 (en) 2,4-pyrimidinediamine compounds and their uses
WO2005070390A3 (en) Mitratapide oral solution
EP2982696A3 (en) Treatment of acute lymphoblastic leukemia
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
MA31245B1 (en) Amides 4 aryl-1, 4-dihydro-1,6-napteridine exchanger and their use.
WO2007103105A3 (en) Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
WO2007064618A8 (en) Methods for the treatment of muscle loss
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
WO2003088923A3 (en) Methods of treating ileus
MX2007002470A (en) Substituted phenylaminothiazoles and use thereof.
WO2006034491A3 (en) Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes
WO2007016352A3 (en) Oral liquid losartan compositions
WO2004017948A8 (en) Use of lck inhibitor for treatment of immunologic diseases
WO2006110588A3 (en) Methods for treating mild cognitive impairment
ATE399165T1 (en) QUINOLINE COMPOUNDS AND USES THEREOF
UA86399C2 (en) Normal;heading 1;heading 2;USE OF 2,5-DIHYDROXYBENZENESULPHONIC ACID IN THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF ANGIODEPENDENT DISEASES
WO2007006732A8 (en) Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
CL2008000982A1 (en) COMPOUNDS DERIVED FROM 5-OXO-ISOXAZOL-CARBOXAMIDA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PROCEDURE OF PRODUCTION OF THE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROTIC DISORDERS, OF METABOLISM OF
WO2006089286A3 (en) Triazadibenzoazulene compounds useful for the treatment and prevention of pain and screening methods therefor compounds useful for the treatment and prevention of pain and screening methods therefor
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
WO2007007182A3 (en) Solid and liquid dosage forms of an antiepileptic agent
WO2007144699A3 (en) Process for the preparation of alfuzosin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 4233/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580005953.6

Country of ref document: CN

122 Ep: pct application non-entry in european phase